US approves 10 drugmakers for 340B rebate pilot, shifting from upfront discounts

The U.S. approved 10 drugmakers to join a 340B pilot program allowing rebates instead of upfront discounts for certain providers. This marks a policy shift in drug pricing mechanics, potentially affecting provider margins and drugmaker revenue. The impact is uncertain pending pilot results.